Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 16/20 | 0.51 |
| ▸ | HTR7 | P34969 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL6996783 | 0.96 | HTR2A (0.51) | DRD2SLC6A4HTR2AHTR7KCNH2 | |
| Ethylene SCHEMBL6998096 | 0.82 | ADRA1D (0.38) | DRD2SLC6A4HTR2AHTR7KCNH2 | |
| Ethylene SCHEMBL6991436 | 0.76 | TDP1 (0.42) | DRD2 | |
| Ethylene SCHEMBL6997790 | 0.75 | KCNH2 (0.41) | DRD2HTR2AKCNH2HTR2C | |
| SCHEMBL9531712 | 0.75 | ADRA1D (0.62) | DRD2SLC6A4HTR2AKCNH2HTR2C | |
| SCHEMBL7884107 | 0.74 | DRD2 (0.70) | DRD2SLC6A4HTR2AHTR2CACHE | |
| SCHEMBL1544931 | 0.73 | ACHE (0.71) | DRD2SLC6A4HTR2AHTR2CACHE | |
| Ethylene SCHEMBL6995999 | 0.73 | DRD2 (0.45) | DRD2SLC6A4HTR2AHTR7KCNH2 | |
| Ethylene SCHEMBL6998179 | 0.73 | DRD2 (0.47) | DRD2SLC6A4HTR2AHTR7KCNH2 | |
| SCHEMBL8871775 | 0.72 | ACHE (0.77) | DRD2SLC6A4HTR2AHTR7HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6316442-B1 | TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES | SUNTORY LIMITED (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | DRD2 402/4885SLC6A4 169/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.